A strategy combining TAM‐/TIDC‐targeted delivery with the dual biological functions of let‐7b (as both a TLR‐7 ligand and an IL‐10 inhibitor) may provide a novel approach for cancer immunotherapy [41]. The gene discussed is IL10; the disease is cancer.